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Acetylsalicylicacid(ASA)iswidelyusedinclinicalpractice.Previousstudiesdoneinratsshowedunexpectedthromboticpotencies
of this drug used at ultra-low doses. This review is the ﬁrst report in which the eﬀects of a wide range of ASA concentration on a
microvessel model of laser-induced thrombus formation and Induced Hemorrhagic Time in animals were largely studied.
1.Introduction
The antithrombotic eﬀectiveness of aspirin is related to its
inhibition of the cyclooxygenase (COX) enzyme that metab-
olizes arachidonic acid to a variety of prostanoids, includ-
ing thromboxane A2 [1]. Platelet-derived cyclooxygenase-1
(COX-1) generates thromboxane A2, a potent vasoconstric-
tor and platelet agonist. The eﬀect of aspirin on platelet
COX-1isirreversible,thusprovidingforonce-dailylow-dose
eﬀectiveness. With the inhibition of platelet COX-1 activity,
there is a decrease in platelet aggregation, leading to a reduc-
ed thromboembolic potential and a commensurate prolon-
ged bleeding time. Thus, it is not surprising that the major
risksassociatedwithaspirinrelatetobleedingcomplications.
Several animal studies showed that aspirin used at strong
concentrations (100mg/kg) prevents thromboembolic com-
plications, and this eﬀect is associated with the important
hemorrhagic side eﬀects; these eﬀects were also observed in
clinical studies [2, 3].
Recently published surveys have warned against the in-
creased risk of aspirin discontinuation, which includes acute
coronary problems, stent stenosis, acute myocardial infarc-
tion, ischemic stroke, and lower limb ischemia [4–12].
Toexplaintheseeventswehypothesizedareboundeﬀect.
Afteronedoseof100mg/kgofaspirin,ratswerestudiedwith
a Laser-Induced Thrombosis (LIT) model every 2 days for
a total period of 16 consecutive days. In the groups studied
at days 8 and 10, increased thromboembolic complications
were found, corroborating the epidemiological evidence
[13]. Similar results were published recently, showing that
discontinuation of aspirin, but not thienopyridines, signiﬁ-
cantly increased the risk of stent stenosis around 7 days after
withdrawal [14]. Increased stent thrombosis was described
by Eisenberg as being caused by variability in platelet res-
ponseorareboundeﬀect.Thisincreasedriskofstentthrom-
bosis added to increased acute myocardial infarction and
stroke risk makes this eﬀect especially dangerous. This pro-
thrombotic mechanism is not well understood. In another
study, we hypothesized that this eﬀect could be due to the
residual eﬀects of aspirin. The use of extremely low concen-
trationsofaspirinprovedtobeasprothromboticastheeﬀect
observed several days after one high dose of aspirin [2].
In an attempt to explain these prothrombotic eﬀects,
we studied LIT with selective inhibitors of COX 1 (SC-560)
and 2 (NS-398). The eﬀect of low concentration aspirin was
more marked after COX 1 inhibition and was blunted after
COX2selectiveinhibition.Moreover,COX2selectiveinhibi-
tion and aspirin at ultra low concentrations had similar pro-
thrombotic eﬀects on the rat [15], suggesting that this eﬀect
was possibly related to COX 2 inhibition [16]. To conﬁrm
these results, we hypothesized the inhibition of COX 2 by
ultra-low concentrations of aspirin and designed an exper-
iment using 72 normal male mice, 72 genetically modiﬁed
male homozygote mice without COX 1 (COX 1 −/−), and 72
genetically modiﬁed male homozygote mice without COX 2
(COX 2 −/−), where we studied induced hemorrhage time
(IHT) and LIT to evaluate primary hemostasis.2 Thrombosis
2.Effects ofCOX SelectiveInhibitionin
AssociationwithAspirininRats
2.1. Material and Methods
2.1.1.Animals. MaleWistarrats(200–250g)purchasedfrom
DelpreBreedingCenter(St.Doulchard,France)werehoused
separately and acclimatized before use under conditions of
controlled temperature (25 ± 2◦C) and illumination (12h
light/dark cycle). They were fed with standard rat chow and
water ad libitum. Animals received care in compliance with
the European Convention of Animal Care.
2.1.2. Induced Hemorrhagic Time. An experimental model of
Induced Hemorrhagic Time (IHT) was performed 10 min-
utes before laser-induced thrombosis. The rat tail was im-
mersed in water for 5 minutes at 37◦C and sectioned 6mm
from the extremity. The IHT measured corresponded to the
time between tail sectioning and the end of bleeding, expres-
sed in seconds.
2.1.3. Thrombus Induction. Animals were anesthetized with
200mg/kg of thiopental sodium (Pentothal, Abbott Labo-
ratories, France), and a median laparotomy was performed.
The intestinal loop was placed on the microscope table and
vascular lesions were induced by an argon laser (Stabilite
2016, Spectra Physics, France). The wavelength used was
514nm and the energy was adjusted to 120mW. The laser
beamwasappliedfor1/15sec.Thedynamiccourseofthrom-
bus formation was continuously monitored and recorded by
placing the laser beam coaxially into the inverted light beam
path of the microscope (Axiovert, Zeiss, France). Micro-
scopic images were recorded through a digital camera (Bas-
ler, Vision Technologies, DX L107, color camera CCD) cou-
pled to a computer and a Dell monitor. A schematic view of
the apparatus used has been previously described [17].
Arterioles between 15 and 25µm diameter were used. The
parameters assessed were the number of emboli removed
by blood ﬂow and the duration of embolization (time bet-
ween ﬁrst and last emboli occurring during a 10-minute
observation period).
2.1.4. Drugs Tested. The amounts of 1mg/mL and 100mg/
mL are obtained by dilution of a solution of Acetylsalicylate
(Aspegic, Sanoﬁ-synthelabo, France). Aspirin dilutions were
prepared as follows: 1g of pure, ﬁnely powdered aspirin was
suspended in 99mL of alcohol (70◦). After being vigorously
shaken, 1mL of this dilution was then mixed with 99mL
of distilled water and vigorously shaken (dilution 1). The
last process was repeated until obtaining desired dilutions.
After being vigorously shaken, 1mL of this dilution was then
mixed with 99mL of distilled water and vigorously shaken.
The last process was repeated until obtaining desired dilu-
tions: Dil 5, Dil 9, and Dil 15. Sterilized water (placebo) or
aspirin were subcutaneously administered at a ﬁnal volume
of 1mL/kg. The groups were treated with placebo or aspirin
in 100mg/kg, 1mg/kg or dilutions 5, 9, or 15.
SelectiveinhibitorsofCOX1,SC-560,andofCOX2,NS-
398 were purchased from Cayman Chemical, (Ann Arbor
Michigan, USA). They were administered per os at doses of
2.5, 5.0, 7.5, or 10mg/kg body weight, suspended in 0.5%
carboxymethylcellulose (CMC) at a ﬁnal volume of 1mL/kg.
The CMC solution was used as placebo.
2.1.5. Protocol. Two hundred Wistar rats were randomly di-
vided into 20 groups (n = 10 rats/group). SC-560 or NS-
398 (2.5; 5; 7.5; 10mg/kg) or association of both inhibitors
(10mg/kg) was administered intragastrically 90min before
the laser procedure. One ultra-low dose of aspirin 1mL/kg
b.w. was injected subcutaneously, 60min before the laser
procedure. Separated groups were injected with placebo.
2.1.6. Statistical Analysis. Data are expressed as Mean ±
Standard Error (SEM) and were compared using Student’s
parametrict-testoraone-wayANOVAtestfollowedbyDun-
nett’s or Bonferroni’s multiple comparison test when appro-
priate(P<0.05wasconsideredsigniﬁcant).GraphPadPrism
version 4.0 (GraphPad Software, San Diego, Calif, USA) was
used for statistical analysis.
2.2. Results
2.2.1. Eﬀects of Products Tested on Induced Hemorrhagic Time.
The administration of ULDA reduced the IHT when com-
pared to the control group (P<0.002). The administration
of a COX-1-speciﬁc inhibitor (SC-560) at diﬀerent doses
signiﬁcantly and dose dependently increased the IHT (P<
0.01). This hemorrhagic side eﬀect of the COX-1-speciﬁc
inhibitor was neutralized by the administration of ULDA.
The administration of a COX-2-speciﬁc inhibitor (NS-
398) with or without ULDA did not signiﬁcantly modify the
IHTwhencomparedtoplacebo.ULDAshortenedIHTinthe
respective group when compared to groups with 2.5, 5, and
7.5mg/kg of NS 398 and placebo (P<0.01). The group with
10mg/kg of Ns 398 had an eﬀect similar to ULDA.
The combined administration of SC-560 and NS-398
resulted in a prolonged IHT (P<0.01), an eﬀect that was
normalized by ULDA injection. The result of all the three
treatments was a mild nonsigniﬁcant modiﬁcation of the ef-
fect of ULDA.
2.2.2. Eﬀects of Products Tested on Laser-Induced Thrombosis.
Compared to the control, the administration of ULDA
signiﬁcantly increased the number of emboli (P<0.001)
and the duration of embolization (P<0.01). On the other
hand, the administration of a COX-1-speciﬁc inhibitor (SC-
560) signiﬁcantlydecreasedthenumber ofemboli (P<0.05)
and the duration of embolization (P<0.05) compared to
thecontrol.However,thisantithromboticeﬀectofthisCOX-
1-speciﬁc inhibitor was neutralized by the administration of
ULDA.
In contrast, the administration of a COX-2-speciﬁc inhi-
bitor (NS-398) compared to the control group signiﬁcantly
increased the number of emboli at three doses studied (P<
0.05) and aﬀected the duration of embolization (P<0.05)
at the two highest doses used. ULDA administration did not
enhance the prothrombotic eﬀect of this COX-2-speciﬁc in-
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The administration of both inhibitors signiﬁcantly de-
creased the number of emboli (P<0.01) and the duration of
embolization (P<0.01) when compared to placebo and in-
creased the IHT (P<0.01). These eﬀects were normalized by
the injection of ULDA.
The mechanism of this eﬀect is not clearly understood.
As COX inhibition is the main mechanism of the eﬀect of
aspirin, COX inhibitors were used to try to understand the
action of ULDA. COX 1 is a constitutive enzyme responsible
for the production of TXA2 in platelets. For the above-ex-
plained reasons, COX 1 inhibition exerts an antithrombotic
inﬂuence. COX 2, though inducible, has been claimed to be
constitutive in many tissues, including the vascular endothe-
lium. The chronic selective inhibition of COX 2 has been
blamed for being prothrombotic and causing serious vascu-
lar complications such as myocardial infarction and stroke
[18].
ULDA exerted a prothrombotic eﬀect in the control
groups, signiﬁcantly shortened IHT and signiﬁcantly in-
creased the number of emboli and the duration of emboliza-
tion. COX 1 selective inhibition had a clear antithrombotic
eﬀect expressed as a decreased number of emboli, decreased
duration of embolization, and a prolonged IHT. This action
is probably expressing TXA2 production inhibition in the
platelet. Despite this antithrombotic eﬀect, injection of
ULDA induced a clear, signiﬁcant trend to normalization of
these values. COX 1 inhibition with sc-560 showed a dose-
eﬀect curve by prolonging IHT with each COX 1 inhibitor
dose increment. Almost each value at diﬀerent doses of inhi-
bitor was decreased after ULDA administration, the diﬀere-
nce being more pronounced at the higher doses. The data
suggest that COX1 inhibition and ULDA have opposite ef-
fects and that COX 1 inhibition does not reduce the eﬀect of
ULDA.
The inhibition of COX 2 with NS-398 produced the op-
posite eﬀects to laser-induced thrombus formation, since
there was a clear prothrombotic activity as shown by an in-
creased number of emboli and longer duration of emboliza-
tion. Shear stress is surely increased in the laser-induced
thrombosis method, as the lesion decreases the diameter of
the vessel, thereby increasing velocity and shear stress.
Although a slight non-signiﬁcant increase in IHT was ob-
served with the lowest doses of NS 398, the highest doses led
to values close to placebo values. The COX 2 inhibitor and
ULDA had similar eﬀects in the laser-induced thrombosis
study and in IHT with the highest dose of COX 2 inhibitor.
There was no change in the response to ULDA after any of
the four diﬀerent doses of NS-398 with regard to number
of emboli, duration of embolization, or IHT, suggesting a
common pathway of eﬀect. When the combination of both
COX inhibitors was used in the same rat, the result was not
substantially diﬀerent from the results obtained only with
COX 1 inhibition. The present study suggests that the se-
lective inhibition of COX 1 or combined inhibition of COX
1 and 2 have clear antithrombotic eﬀects, as observed by a
prolonged IHT and the increased laser-induced thrombosis.
However, COX 2 selective inhibition and ULDA showed a
powerful prothrombotic action in the laser-induced throm-
bosis study. As demonstrated in the above-mentioned sur-
veys, the thromboembolic complications were observed sev-
eral days after aspirin withdrawal. A similar delay of 8 to 10
days was observed for a prothrombotic eﬀect in the laser-in-
duced study after a single administration of an antithrom-
botic dose of aspirin (100mg/kg b.w.) in the rat [13]. The
possibility of a late inhibition of endothelial COX 2 could
be the link between the prothrombotic eﬀect of aspirin and
the eﬀect of ULDA. Laser-induced thrombosis seems to be a
very sensitive method for analyzing the in vivo interaction of
platelets and endothelium and the production of thrombi in
the microcirculation.
In conclusion, ULDA administered alone demonstrates
prothrombotic activities increases the number of emboli and
the duration of embolization. COX-1-speciﬁc inhibition has
antithrombotic and hemorrhagic eﬀects in rats. These eﬀects
weremodiﬁedbyULDAadministration.Added,COX-2-spe-
ciﬁc inhibition has prothrombotic activities that were not
enhanced by the administration of ULDA. These results sug-
gest that the prothrombotic eﬀects of ULDA may occur via a
COX-2 pathway rather than via a COX-1 route. This would
explain the reported thromboembolic complications obser-
ved several days after aspirin withdrawal, a phenomenon us-
uallyinterpretedasareboundeﬀect.However,thisstudysug-
gests that this thromboembolic complication is more likely a
direct eﬀect of ULDA via COX-2 inhibition.
3. Effect of Aspirin in COX 1 −/− or
COX 2 −/− Knockout Mice
3.1. Material and Methods
3.1.1. Animals. Normal mice from centre d’´ elevage (Depre
Saint Doulchard, France) and the male homozygous COX
1 −/− and COX 2 −/− mice purchased from Taconic
Farms Inc. (Hudson City Centre, NY, USA) were housed se-
parately under conditions of controlled temperature and
illumination. Knockout animal is an animal into which
one speciﬁcally introduces, by homologous recombination,
a modiﬁcation into the coding structure of gene or his regu-
lating elements in order to inhibit or to modify the operation
of gene in the studied organization.
They were fed with standard mouse chow and water ad
libitum. Animals received care in compliance with the Euro-
pean Convention of Animal Care.
3.1.2.InducedHemorrhagicTime(IHT). IHTwasperformed
10 minutes before thrombosis induction by laser. The tail of
the mouse was immersed in water for 5 minutes at 37◦Ca n d
sectioned 6 mm from the extremity and is expressed as the
timebetweenthetailsectionandtheendofbleeding,expres-
sed in seconds.
3.1.3. Thrombus Induction. Animals were anaesthetized with
200mg/kg of Ketamine (Panpharma, France). After laparo-
tomy, the intestinal loop was placed on the microscope and
vascular lesions were induced by Argon laser (Stabilite 2016,
Spectra Physics, France). Two parameters were assessed: the
number of emboli (NE) removed from the thrombus by4 Thrombosis
Table 1: Eﬀects of aspirin on the platelet activity in normal mice.
ASA Placebo 100mg/kg 1mg/kg Dil 5 Dil 9 Dil 15
IHT (sec) 113.9 ±24.64 363.3 ±93.3
∗ 110.5 ±97.3 119.2 ±36.7 138.8 ±24.1 103.6 ±78.8
NE 4.8 ±1.51 .1 ±0.7
∗ 3.0 ±1.2
∗ 6.4 ±1.95 .6 ±1.99 .4 ± 1.7
∗
DE (min) 2.1 ±0.70 .3 ±0.4
∗ 1.1 ±0.6
∗ 3.0 ±0.82 .2 ±0.74 .1 ± 1.5
∗
∗P < 0.05 indicates a statistically signiﬁcant diﬀerence with the placebo group.
Table 2: Eﬀects of aspirin on the platelet activity in COX 2 −/− knockout mice.
ASA Placebo 100mg/kg 1mg/kg Dil 5 Dil 9 Dil 15
IHT (sec) 327.3 ±103.8 212.2 ±109.3 288.1 ±98.7 300.9 ±131.4 336.5 ±77.7 245.5 ±123.9
NE 9.0 ±3.93 .29 ±2.36
∗ 7.0 ±4.56 .50 ±3.25 .25 ±3.24 8.11 ±2.76
DE (min) 4.5 ±1.73 1.29 ±1.11
∗ 3.0 ±2.42 .38 ±1.51 2.25 ±1.58 3.55 ±1.01
∗P < 0.05 indicates a statistically signiﬁcant diﬀerence with the placebo group.
Table 3: Eﬀects of aspirin on the platelet activity in COX 1 −/− knockout mice.
ASA Placebo 100mg/kg 1mg/kg Dil 5 Dil 9 Dil 15
IHT (sec) 255.7 ±92.23 288.3 ±77.0 287.8 ±79.2 275.0 ±107.2 229.3 ±80.63 164.8 ±88.9
∗
NE 2.45 ±1.21 1.36 ±1.03
∗ 2.09 ±1.42 .98 ±1.05 2.8 ±1.14 4.6 ±2.01
∗
DE (min) 1.09 ±0.94 0.36 ±0.67 0.73 ±0.79 1.3 ±0.48 1.3 ±0.67 2.0 ±0.82
∗
∗P < 0.05 indicates a statistically signiﬁcant diﬀerence with the placebo group.
blood ﬂow after an injure produced by the laser shot and the
duration of embolisation (DE), expressed in minutes.
3.1.4. Drugs Tested. The amounts of 1mg/mL and 100mg/
mL are obtained by dilution of a solution of acetylsalicylate
(Aspegic, Sanoﬁ-synthelabo, France). Aspirin dilutions were
prepared as follows: 1g of pure, ﬁnely powdered aspirin was
suspended in 99mL of alcohol (70◦). After being vigorously
shaken, 1mL of this dilution was then mixed with 99mL of
distilled water and vigorously shaken (dilution 1). The last
process was repeated until obtaining desired dilutions: 4
times (dilution 5), 8 times (dilution 9), and 14 times (dilu-
tion 15). Sterilized water (placebo) or aspirin were subcu-
taneously administered at a ﬁnal volume of 1mL/kg mouse
weight. The groups were treated with placebo or aspirin in
100mg/kg, 1mg/kg or dilutions 5, 9, or 15 (n = 9–11mice/
group).
3.1.5. Distribution of Groups. COX 1 −/− or COX 2 −/−
Knockout mice were distributed in 6 groups (n = 12/group),
respectively.
Group 1: placebo (sterilized water).
Group 2: aspirin 100mg/kg.
Group 3: aspirin 1mg/kg.
Group 4: aspirin dilution 5.
Group 5: aspirin dilution 9.
Group 6: aspirin dilution 15.
3.1.6. Statistical Analysis. Data are expressed as mean ± SD
and compared using one-way analysis of variance (ANOVA)
followed by Dunnett’s multiple comparison test. A value of
P<0.05wasconsideredassigniﬁcant.Statisticalcalculations
were performed using GraphPad Prism version 4.00 for
Windows.
3.2. Results (Tables 1, 2,a n d3). The IHT model is especially
sensitive to the eﬀect of high doses of ASA. However, mice
without COX 1 did not react to the higher doses of ASA.
The highest dilution (Dil 15) of ASA signiﬁcantly shortened
IHT in COX 1-deﬁcient mice, conﬁrming that its strong pro-
thrombotic eﬀect is not mediated by COX 1. No signiﬁcant
changes in IHT were observed after ASA in COX 2-deﬁcient
mice.
NE and DE with placebo in COX 1-deﬁcient mice were
clearly decreased when compared to COX 2-deﬁcient mice,
highlightingtheimportanceofCOX1generatedTXA2 inthe
platelets. The highest dose of aspirin produced a decreased
NE in COX 1-deﬁcient mice.
4. Discussion
Administered at high dose (100mg/kg), aspirin showed po-
tent antithrombotic eﬀects. This beneﬁt action of aspirin is
associated with risk of hemorrhagic side eﬀects.
When administered at 1mg/kg, aspirin prevents throm-
boemboliccomplication,butinlessimportantmanner,com-
pared with 100mg/kg. This moderated antithrombotic eﬀect
is not associated with an increased hemorrhagic risk.
The presence of ultra-low doses of aspirin, which is
equivalent to high dilution, increased the thromboembolic
complications without eﬀect on hemorrhage. These residual
concentrations of aspirin could explain the advent of throm-
boembolic complications after aspirin discontinuation. ThisThrombosis 5
phenomenonrequired8to12daystoexpressinclinicalstud-
ies and would explain the appearance of the secondary side
eﬀects observed several days after the treatment discontinua-
tion.
These repeated phenomena could induce complications
which are not related to the administered substances.
In conclusion, aspirin at strong dose (100mg/kg) pre-
vents thromboembolic complications in the rat with an im-
portant hemorrhagic risk. With lower doses (1mg/kg) aspi-
rin still preserves a light antithrombotic activity but without
increasing the hemorrhagic risk.
Ultra-low doses of aspirin induce a risk of thromboem-
bolic complications which are not associated with an action
on the hemorrhage.
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